STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Xylo Technologies Ltd. American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

L.I.A. Pure Capital Ltd. and its sole shareholder and CEO, Kfir Silberman, report beneficial ownership of 4,912,827 ordinary shares (approximately 9.59% of 51,241,661 outstanding) of Xylo Technologies Ltd. The reporting persons hold sole voting and dispositive power over these shares. The ADSs described were acquired for an aggregate purchase price of approximately $512,856 using Pure Capital funds. The filing discloses that Xylo furnished a Form 6-K stating it obtained the Israeli tax ruling required for the Arrangement, initiated closing procedures, and will de-list ADSs from Nasdaq on August 22, 2025. From that date, ADS holders will be entitled to $5.25 per ADS in cash, subject to withholding taxes, and the depositary will close books for issuances after close of business on August 21, 2025.

Positive
  • 9.59% beneficial ownership disclosed, providing transparency about significant shareholders
  • Issuer obtained required Israeli tax ruling and initiated closing procedures for the Arrangement
  • ADS holders entitled to $5.25 per ADS in cash, a definitive exit mechanism announced
  • Reporting persons acquired ADSs with disclosed aggregate purchase price of $512,856
Negative
  • ADSs will be de-listed from Nasdaq on August 22, 2025, eliminating public market liquidity for ADS holders
  • Depositary will close books for issuances and cancellations after close of business on August 21, 2025, and the deposit agreement will terminate per the depositary’s notice
  • Reporting persons executed sizable sales on August 7, 2025 (including blocks of 23,223 and 18,270 ADSs), reflecting active position changes

Insights

TL;DR: Amendment confirms a near-term delisting and cash consideration of $5.25 per ADS and shows a 9.59% beneficial stake by the reporting persons.

The filing is materially significant because it documents both the reporting persons' meaningful stake in XYLO and concrete execution steps toward a transaction that will remove ADS liquidity for public holders. The reported aggregate purchase price of roughly $512,856 clarifies the funding source and scale of recent acquisitions. The Form 6-K disclosures — tax ruling obtained, closing procedures initiated, Nasdaq delisting effective August 22, 2025, and BNY's planned depositary actions — are decisive operational steps that directly affect timing and execution of the Arrangement.

TL;DR: Reporting persons exercise sole control over 9.59% of shares; delisting and depositary termination are material governance events.

The amendment highlights concentrated ownership with sole voting and dispositive power held by Pure Capital and its sole shareholder, which is material for governance and minority-holder considerations. The announced delisting, depositary notice and termination mechanics (BNY closing book after August 21, 2025) change the company’s public governance framework and shareholder rights. These are substantive corporate actions that warrant attention from regulators and affected holders.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Includes 4,635,400 ordinary shares underlying 115,885 ADSs held by L.I.A Pure Capital Ltd. and 277,427 ordinary shares registered in book-form by the Issuer's transfer agent (2) Based on 51,241,661 ordinary shares outstanding as of April 17, 2025 (based on the Issuer's Notice and Proxy Statement in connection with the special general meetings, furnished to the Securities and Exchange Commission on April 21, 2025).


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Includes 4,635,400 ordinary shares underlying 115,885 ADSs held by L.I.A Pure Capital Ltd. and 277,427 ordinary shares registered in book-form by the Issuer's transfer agent (2) Based on 51,241,661 ordinary shares outstanding as of April 17, 2025 (based on the Issuer's Notice and Proxy Statement in connection with the special general meetings, furnished to the Securities and Exchange Commission on April 21, 2025).


SCHEDULE 13D


L.I.A. Pure Capital Ltd.
Signature:/s/ Kfir Silberman
Name/Title:Kfir Silberman
Date:08/12/2025
Kfir Silberman
Signature:/s/ Kfir Silberman
Name/Title:Kfir Silberman
Date:08/12/2025

FAQ

What percentage of XYLO does L.I.A. Pure Capital and Kfir Silberman beneficially own?

They beneficially own 4,912,827 ordinary shares, representing approximately 9.59% of the issued and outstanding ordinary shares.

How much cash will XYLO ADS holders receive under the announced Arrangement?

Holders of ADSs will be entitled to receive $5.25 per ADS, subject to applicable withholding taxes.

When will XYLO ADSs be de-listed from Nasdaq?

The issuer stated that XYLO ADSs will be de-listed from Nasdaq on August 22, 2025.

What funding was used to acquire the ADSs reported in the Schedule 13D/A?

The ADSs were acquired using the funds of Pure Capital at an aggregate purchase price of approximately $512,856.

Will the depositary continue ADS issuances after mid-August 2025?

No; BNY will close its books for all issuances and cancellations after close of business on August 21, 2025, and the deposit agreement will terminate as described.
Xylo Technologies

NASDAQ:XYLO

XYLO Rankings

XYLO Latest News

XYLO Latest SEC Filings

XYLO Stock Data

6.49M
1.17M
9.05%
5.84%
1.01%
Medical Devices
Healthcare
Link
Israel
Tel Aviv